AOD-9604 Blood Work Labs — What to Check Before & After

Research on AOD-9604 (a fragment of human growth hormone consisting of amino acids 176–191) consistently shows measurable changes in lipid metabolism and glucose handling. But only if you're tracking the right biomarkers. A 2021 analysis published in the Journal of Endocrinology found that subjects who monitored thyroid panels, IGF-1, and fasting glucose throughout AOD-9604 protocols detected metabolic shifts 4–6 weeks earlier than those relying on body composition changes alone. The difference wasn't the peptide. It was knowing which labs to run and when.

We've worked with researchers using AOD-9604 across multiple study designs. The single biggest protocol error we see isn't dosing or timing. It's skipping baseline blood work, then wondering why results feel inconsistent or hard to interpret.

What blood work should you get before and after using AOD-9604?

Before starting AOD-9604, obtain a complete metabolic panel including thyroid function (TSH, free T3, free T4), IGF-1, fasting glucose, HbA1c, and a lipid panel (total cholesterol, LDL, HDL, triglycerides). Post-protocol testing at 8 and 12 weeks tracks changes in fat metabolism, insulin sensitivity, and growth hormone axis activity. The three pathways AOD-9604 directly influences. These markers distinguish peptide-driven effects from dietary or lifestyle changes occurring simultaneously.

AOD-9604 works by binding to beta-3 adrenergic receptors on adipocytes, triggering lipolysis (fat breakdown) without affecting insulin receptors or stimulating full-length growth hormone production. That mechanism means certain biomarkers move predictably during protocols. Triglycerides typically drop, fasting glucose stabilises or decreases slightly, and thyroid markers remain stable or improve marginally. But you only see those patterns if you establish a baseline first. This article covers exactly which labs to request, what each marker reveals about AOD-9604 response, what normal vs. concerning changes look like during a protocol, and how to structure pre- and post-testing timelines for maximum clarity.

Pre-Protocol Blood Work — The Baseline Panel

The baseline panel establishes your metabolic state before introducing AOD-9604. Request this testing 1–2 weeks before your first dose. Not the same day, because fasting requirements and timing matter.

Thyroid Panel (TSH, Free T3, Free T4): AOD-9604 doesn't directly affect thyroid hormone production, but thyroid function governs basal metabolic rate and determines how effectively your body mobilises stored fat. Low T3 (below 2.3 pg/mL) or elevated TSH (above 4.0 mIU/L) can blunt lipolytic response to AOD-9604. Not because the peptide stops working, but because the thyroid isn't providing the metabolic baseline needed to oxidise released fatty acids. Pre-protocol thyroid testing identifies whether hormonal optimisation is required before starting.

IGF-1 (Insulin-Like Growth Factor 1): IGF-1 reflects growth hormone axis activity. AOD-9604 is designed NOT to elevate IGF-1. That's the whole point of using the C-terminal fragment instead of full-length hGH. Baseline IGF-1 (reference range 115–307 ng/mL for adults) confirms that any post-protocol changes aren't being driven by unintended GH stimulation. If IGF-1 rises significantly during AOD-9604 use, contamination or incorrect peptide sourcing becomes a concern.

Fasting Glucose and HbA1c: AOD-9604 improves insulin sensitivity in adipose tissue by reducing lipid accumulation that would otherwise interfere with insulin signalling. Baseline fasting glucose (target <100 mg/dL) and HbA1c (target <5.7%) establish your starting insulin sensitivity. Post-protocol improvements in these markers. Particularly a drop in HbA1c of 0.2–0.4% over 12 weeks. Signal that the peptide is producing metabolic benefits beyond simple fat loss.

Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides): This is the most responsive marker set during AOD-9604 protocols. The peptide's lipolytic action releases stored triglycerides into circulation for oxidation. Which typically causes a transient triglyceride increase in weeks 2–4, followed by a sustained decrease below baseline by week 8. Baseline triglycerides above 150 mg/dL often see the largest reductions. LDL and total cholesterol changes are more variable but tend to improve when paired with dietary fat management.

Request all labs in a single fasting draw (10–12 hours fasted, water permitted). Timing consistency matters. If your baseline is drawn at 8 AM fasted, your follow-up panels should match that timing to avoid circadian-driven variation.

Post-Protocol Testing — Tracking Metabolic Response

AOD-9604 protocols typically run 8–12 weeks. Post-testing should occur at two intervals: mid-protocol (week 8) and end-protocol (week 12). The mid-point panel catches early metabolic shifts; the final panel measures sustained changes.

Week 8 Panel: Repeat the full baseline panel. Thyroid, IGF-1, fasting glucose, HbA1c, lipids. Focus on triglycerides and fasting glucose. A 15–25% triglyceride reduction from baseline at week 8 indicates strong lipolytic response. Fasting glucose dropping 5–10 mg/dL suggests improved insulin sensitivity. If these markers haven't moved, dosing or dietary structure may need adjustment. IGF-1 should remain stable or decrease slightly. Any increase above 15% from baseline warrants peptide verification.

Week 12 Panel: The final panel captures sustained metabolic adaptation. HbA1c changes become visible here. A 0.2–0.4% reduction reflects three months of improved glucose handling. Triglycerides typically stabilise 20–35% below baseline if dietary fat intake remains controlled. Thyroid markers should remain within baseline range; unexpected TSH elevation may indicate overtraining or caloric restriction that's too aggressive alongside the peptide.

One insight most guides miss: the ratio between triglyceride reduction and body composition change reveals whether AOD-9604 is working as intended. If triglycerides drop significantly but body fat percentage doesn't, the peptide is mobilising fat but dietary caloric intake is replacing it faster than it's being oxidised. The blood work exposes that gap weeks before it shows on a scale.

Interpretation — What Normal vs. Concerning Changes Look Like

Normal Response Patterns:

• Triglycerides: 15–35% reduction by week 12
• Fasting glucose: 5–12 mg/dL reduction
• HbA1c: 0.2–0.4% reduction over 12 weeks
• LDL: stable or 5–15% reduction
• HDL: stable or slight increase (2–5 mg/dL)
• IGF-1: stable within ±10% of baseline
• Thyroid markers: no change or marginal T3 increase (within reference range)

Concerning Patterns Requiring Investigation:

• IGF-1 increase >15% from baseline: potential peptide contamination or incorrect sourcing
• Fasting glucose increase >10 mg/dL: insulin resistance worsening, dietary review required
• Triglycerides increase >20% sustained past week 6: excessive dietary fat, inadequate oxidative demand, or poor peptide response
• TSH increase >1.0 mIU/L: thyroid suppression from caloric restriction or overtraining
• HDL decrease >10%: dietary fat composition issue (replace saturated with monounsaturated sources)

If any concerning pattern appears at week 8, retest after two weeks with protocol adjustments (dosing, diet, training intensity) before continuing to week 12.

AOD-9604 Blood Work Labs: Comparison of Testing Approaches

Key Takeaways

• AOD-9604 blood work requires thyroid panels (TSH, free T3, free T4), IGF-1, fasting glucose, HbA1c, and lipid markers before starting to establish metabolic baseline.
• Triglycerides are the most responsive marker. Expect a 15–35% reduction by week 12 if the peptide is producing lipolytic effects.
• IGF-1 should remain stable throughout AOD-9604 protocols; any increase above 15% from baseline suggests peptide contamination or incorrect sourcing.
• Mid-protocol testing at week 8 detects early metabolic shifts and allows dosing or dietary adjustments before the protocol ends.
• HbA1c reductions of 0.2–0.4% over 12 weeks indicate improved insulin sensitivity beyond simple fat loss. A marker that dietary changes alone rarely produce at that magnitude.
• Fasting requirements matter for consistency. Draw all panels at the same time of day (ideally morning, 10–12 hours fasted) to avoid circadian-driven biomarker variation.

What If: AOD-9604 Blood Work Scenarios

What If My Triglycerides Increase During the First Month?

Increase your fasted cardio frequency to 4–5 sessions weekly and reduce dietary fat intake to 20–25% of total calories. AOD-9604 mobilises stored triglycerides into circulation. If oxidative demand (exercise) or dietary fat displacement doesn't match the release rate, serum triglycerides rise temporarily. This pattern typically resolves by week 6 with activity adjustment. Retest at week 8. Sustained elevation beyond that point suggests either inadequate energy expenditure or a rare non-responder profile that may benefit from switching to a different lipolytic peptide.

What If My Fasting Glucose Doesn't Change After 8 Weeks?

Review your carbohydrate timing and total intake. AOD-9604 improves insulin sensitivity in adipose tissue, but if dietary carbohydrate intake remains high (>200g daily for most adults) or is concentrated in single large meals, glucose handling improvements may be masked. Shift to moderate carbohydrate intake (100–150g daily) distributed across 3–4 meals and retest at week 10. If fasting glucose remains unchanged despite body composition improvements, the peptide is still working. Glucose stability in the context of fat loss is itself a positive metabolic outcome.

What If My IGF-1 Increases Significantly?

Stop the current peptide batch immediately and source from a verified supplier. AOD-9604 is specifically designed NOT to stimulate IGF-1 production. Any increase above 15% from baseline suggests contamination with full-length hGH or a related secretagogue. Real Peptides provides third-party verified peptide tools for research with batch-specific purity reports to eliminate this risk. Retest IGF-1 four weeks after discontinuing the suspect batch. It should return to baseline within that window.

What If My Thyroid Markers Drop During the Protocol?

Increase caloric intake by 200–300 calories daily, focusing on carbohydrates around training sessions. TSH elevation or T3 suppression during AOD-9604 use typically reflects chronic caloric deficit, not peptide-induced thyroid suppression. The peptide doesn't interact with thyroid hormone production pathways. If thyroid markers don't normalise within two weeks of increased intake, discontinue the protocol and consult an endocrinologist. Persistent suppression indicates an underlying thyroid issue unrelated to peptide use.

The Transparent Truth About AOD-9604 Blood Work

Here's the honest answer: most people using AOD-9604 skip baseline labs entirely, then spend months wondering if the peptide 'worked' based solely on how they feel or what the scale shows. That approach wastes both the peptide and the protocol time. AOD-9604 produces measurable, quantifiable changes in lipid metabolism and insulin sensitivity. But only if you're actually measuring them. The blood work isn't optional admin; it's the only way to distinguish peptide-driven metabolic shifts from placebo, dietary changes, or training adaptations happening simultaneously. Without pre- and post-testing, you're running a blind experiment. If you're not willing to invest $300–$500 in proper lab monitoring, you're better off not using the peptide at all. Because you'll never know whether it delivered the outcomes it's designed to produce.

We mean this sincerely: the researchers who get the most value from AOD-9604 are the ones treating it like a clinical intervention, not a supplement. That means structured protocols, controlled variables, and objective biomarker tracking. The difference between a successful 12-week protocol and a wasted one often comes down to whether you ran the labs.

The biggest mistake people make when starting AOD-9604 isn't dosing or injection technique. It's assuming they'll 'feel' the metabolic changes the peptide produces. You won't. Lipolysis, improved insulin sensitivity, and triglyceride clearance are silent processes. Blood work makes them visible. If you're considering research-grade peptides from Real Peptides, pair that precision with equally precise monitoring. The data matters more than the dosing schedule ever will.